drugset / Trial / NCT01852331
Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia
Phase 2
Completed
103 enrolled
The University of Hong Kong
Capital Medical University · collabKowloon Hospital, Hong Kong · collabQueen Mary Hospital, Hong Kong · collabXijing Hospital · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The investigators hypothesize that Peony-Glycyrrhiza Decoction (PGD) adjunctive therapy could reduce the incidence of prolactin (PRL)-related adverse events in patients with schizophrenia and suppress antipsychotic-induced elevation of PRL levels. This is a placebo-controlled trial conducted in schizophrenic patients to determine whether PGD adjunctive treatment could produce greater biochemical and clinical improvement on hyperprolactinemia (hyperPRL) compared to placebo treatment.
Timeline
- Start
- 2013-01
- Primary completion
- 2014-04
- Completion
- 2014-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Peony-Glycyrrhiza Decoction | Traditional medicine (herbal / TCM) | 45 g | Oral |